Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...

For parents of children living with significant health issues, it can be hard to find ways to channel fear into hope. For anyone living with major depression and suicidal ideation, it can be hard to ...

J&J is discontinuing the Phase 3 test of its drug, aticaprant, in major depressive disorder “due to insufficient efficacy in the target patient population,” the company said after Thursday’s ...

Major depressive disorder with seasonal patterns, also known as seasonal affective disorder, causes symptoms similar to ...

A new study shows the positive impact gender-affirming hormone therapy, or GAHT, can have on the depression rates for transgender adults.

In a statement released Thursday afternoon, J&J said it will stop developing the drug, called aticaprant, as an add-on ...

The blues and the jitters are very common among people battling chronic pain, a new evidence review says. About 40% of adults ...

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good thing? And is depression weight loss even a thing in the first place?

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...